Puente, J, Pinto, A, Mendez-Vidal, MJ, del Muro, XG, Maroto, P, Vazquez, S, Luque-Caro, R, Anido, U, Strunz-McKendry, T, Upadhyay, A, Montes, J, Nuñez, AO, Portela, JG, Castellano, D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2025; 27(5)DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2.500(Q3/6D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. Jto Clinical And Research Reports. 2025; 6(5)DOI:10.1016/j.jtocrr.2025.100815. PMID:40248457. IF:(Q/D).

Rueda, A, Serna, N, Mangues, R, Villaverde, A, Unzueta, U. Targeting the chemokine receptor CXCR4 for cancer therapies. Biomarker Research. 2025; 13(1)DOI:10.1186/s40364-025-00778-y. PMID:40307933. IF:11.500(Q1/1D).

Wieczorek, SC, Hernández-Alvarez, MI, Parreño, M, Muñoz, JP, Bussaglia, E, Carricondo, M, Ubeda, J, Dubreuil, P, Zorzano, A, Brenet, F, Nomdedeu, JF. D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1. EXPERIMENTAL HEMATOLOGY. 2025; 145DOI:10.1016/j.exphem.2025.104748. PMID:39986568. IF:2.100(Q3/6D).